Journal Home
Search for

Volume 53, Issue 5, Pages 779-789 (May 2009)


View previous. 10 of 38 View next.

Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study

Veterans Affairs Site InvestigatorsRex L. Jamison, MDCorresponding Author Informationemail address, Mei-Chiung Shih, PhD, Donald E. Humphries, PhD, Peter D. Guarino, PhD, James S. Kaufman, MD, David S. Goldfarb, MD, Stuart R. Warren, PharmD, J. Michael Gaziano, MD, Philip Lavori, PhD

Received 7 October 2008; accepted 30 December 2008. published online 09 March 2009.

Background

Abnormalities in the gene regulating methylenetetrahydrofolate reductase (MTHFR) are associated with increased homocysteine levels and increased mortality in normal and chronic kidney disease (CKD) populations.

Study Design

Gene association study.

Setting & Participants

This was a substudy of 677 patients from 21 Veterans Affairs medical centers participating in a randomized clinical trial (Homocysteinemia in Kidney and End-Stage Renal Disease [HOST]) of the effect on all-cause mortality of vitamin-induced lowering of plasma homocysteine levels. Of 677 patients, 213 (31%) were treated by using dialysis (end-stage renal disease [ESRD]) and 464 (69%) had a Cockcroft-Gault estimated creatinine clearance less than 30 mL/min (advanced CKD).

Predictor

Polymorphisms C677T (rs1801133) and A1298C (rs1801131) of the MTHFR gene.

Outcomes

Unadjusted and adjusted all-cause mortality.

Measurements

DNA was extracted from blood samples and amplified by means of polymerase chain reaction.

Results

The adjusted hazard ratio in a recessive model of the relationship between the C677T polymorphism and all-cause mortality in all patients was 1.47 (95% confidence interval, 1.00 to 2.16; P = 0.05). In patients with ESRD with the mutant TT genotype, the adjusted hazard ratio for mortality in all patients was 2.27 (95% confidence interval, 1.07 to 4.84; P = 0.03); patients with advanced CKD showed a similar, although not significant, trend. The risk of myocardial infarction (P = 0.05) and composite risk of myocardial infarction, stroke, lower-extremity amputation, and mortality (P = 0.02) were greater in patients with ESRD with the mutant T allele at nucleotide 677. The overall relationship between the A1298C polymorphism and mortality was not significant (P = 0.6).

Limitations

Participants were 98% men; DNA samples were not obtained at enrollment in HOST; linkage disequilibrium with another causal polymorphism is a potential confounding factor; and power was reduced by the limited number of participants.

Conclusions

These findings provide additional support for the hypothesis that the mutant TT genotype at nucleotide 677 of the gene regulating MTHFR activity may increase the mortality risk in patients with ESRD.

Corresponding Author InformationAddress correspondence to Rex L. Jamison, MD, MB3 Rm 305, M/C HOST 151, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304

 A list of author affiliations appears at the end of this article.

 A list of the Veterans Affairs Site Investigators appears at the end of this article.

 Originally published online as doi:10.1053/j.ajkd.2008.12.023 on March 9, 2009.

 Trial Registration: www.clinicaltrials.gov; study number: NCT00032435.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Barbara Murphy, MD, Mount Sinai School of Medicine) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00061-4

doi:10.1053/j.ajkd.2008.12.023


View previous. 10 of 38 View next.